Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00701259 · ClinicalTrials.gov registry record · Phase 3
Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn
A Phase 3 study of Frequent Heartburn, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 852
- Enrollment target
- 1
- Study location
NCT00701259: Completed Phase 3 study of Frequent Heartburn, sponsored by Novartis.
NCT00701259 is a Phase 3 study of Frequent Heartburn that has completed, run by Novartis. The registered enrollment target is 852 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00701259, a Phase 3 study of Frequent Heartburn, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 852 participants
- Enrollment target
- 1
- Study location
Study Summary
Heartburn, a burning sensation in the chest or throat, occurs in many individuals when acidic stomach contents move upward into the esophagus from the stomach. This study will investigate the safety and efficacy of lansoprazole 15 mg or 30 mg administered once a day in preventing frequent nighttime heartburn.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Lansoprazole
Study Locations (1)
New Jersey
- Not applicable - enrollment complete - Parsippany
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 852 participants |
| Start Date | 2007-01 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
What the finished NCT00701259 record still lists
NCT00701259 is an interventional study that assigns participants to a tested intervention. The registered 852 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher).
The record links to 1 condition, with Frequent Heartburn appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00701259 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00701259 about?
NCT00701259 is a clinical study titled "Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn". Heartburn, a burning sensation in the chest or throat, occurs in many individuals when acidic stomach contents move upward into the esophagus from the stomach. This study will investigate the safety and efficacy of lansoprazole 15 mg or 30 mg administered once a day in preventing frequent nighttime ...
What is the current status of trial NCT00701259?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 852 participants. The study started on 2007-01. Estimated completion is 2007-08.
What conditions does trial NCT00701259 study?
This clinical trial studies the following conditions: Frequent Heartburn.
What interventions are being tested in trial NCT00701259?
The interventions under investigation include: placebo (DRUG), Lansoprazole (DRUG).
Who is sponsoring clinical trial NCT00701259?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00701259 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00701259's enrollment target sits among peer trials
852 385th of 2000 higher than 1,615 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06237452 · 852 participants · Phase 3
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
- NCT06422143 · 851 participants · Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- NCT07005102 · 854 participants · Phase 2
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- NCT07290491 · 854 participants · Phase 3
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia